Denis Johnson Joins Kindeva Drug Delivery as Chief Operating Officer to Lead Global Operations
Kindeva Drug Delivery announced today that it appointed Denis Johnson as its new chief operating officer (COO).
Kindeva Drug Delivery Welcomes Jennifer Riter, New Vice President of Analytical Services
Kindeva Drug Delivery Launches New Analytical Services Global Business Unit
Kindeva Drug Delivery Acquires Summit Biosciences, a Specialized Nasal Drug Development and Manufacturing Organization
ORLANDO, FL / ACCESSWIRE / January 5, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of transdermal pharmaceutical products, today announced it has signed a commercial development and clinical supply agreement for their lead product, Aversa™ Fentanyl, with their partner, Kindeva Drug Delivery, a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products. Under this agreement, Kindeva will perform commercial manufacturing process development and manufacture clinical supplies for the human abuse liability clinical study required by the FDA in support of a New Drug Application (NDA). This new agreement replaces the previous feasibility agreement between the two companies which was focused on adapting Kindeva's commercial transdermal manufacturing process to incorporate AVERSA™ abuse deterrent transdermal technology.
WOODBURY, Minn. & ST. LOUIS & BOSTON--(BUSINESS WIRE)--Kindeva Drug Delivery (Kindeva), a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products, and Orbia Advance Corporation, S.A.B. de C.V. (BMV: ORBIA*) Fluorinated Solutions business (Koura®), a global leader in the development, manufacture, and supply of fluoroproducts and technologies, announced today a co-development collaboration for the conversion from existing marketed pressurised Metered Dose Inhaler (pMDI) products to Koura’s more sustainable and environmentally-conscious medical propellant; HFA 152a, known as Zephex® 152a.
Kindeva Drug Delivery Appoints Brian Schubmehl as Chief Human Resources Officer
Kindeva, a CDMO focused on drug delivery devices, hauled in a 33 million pound sterling ($42.1 million) grant from the U.K.’s Life Sciences Innovation Manufacturing Fund that will be used to bolster the company’s inhaler production and sustainability efforts.
U.K. Government Grant Unlocks £33M Investment With Kindeva Drug Delivery for Greener Inhaler Future